BRISTOL MYERS SQUIBB

📅 Upcoming

🕒 Recent(90d)

News

• Bristol Myers defends pipeline, reinforces later-stage BD interest
  Bristol Myers Squibb is reemphasizing its plan to stave off one of the industry’s most daunting patent cliffs. Speaking to analysts on its earnings call on Thursday, executives at the New Jersey ph…
  endpoints · 3h ago
• BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
  In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…
  biospace · 5h ago
• LENZ cuts 75% of staff as third quarter earnings disappoint
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 7h ago
• BMS walks away from $80M neurodegeneration bet after phase 1
  Bristol Myers Squibb has scrapped a phase 1 program it bet $80 million on just two years ago.
  fiercebiotech · 12h ago
• Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
  Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and…
  biospace · 1d ago
• Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
  Astellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.
  fiercebiotech · 1d ago
• 5 new drug launches that defied industry expectations
  A clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.
  biospace · 1d ago
• Big Pharma is ready to strike, with J&J most likely to buy: Leerink
  The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.
  biospace · 1d ago
• Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
  The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.
  biopharma_dive · 2d ago
• Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
  Artiva Biotherapeutics has halted development of an autoimmune disease cell therapy and laid off 94% of its staff after two patients died and durability data fell short of expectations.
  fiercebiotech · 2d ago